



ISPE San Francisco/Bay Area Chapter

<http://www.atdevents.net/register.php>

Announces an Evening Meeting

CEO Night

Featuring Executives from Bay Area Companies

Tuesday, February 19, 2019

5:00 - 8:00 pm

Meeting Location:

AC Hotel South San Francisco/Oyster Point Waterfront

1333 Veterans Blvd., South San Francisco, CA 94080

Schedule: 5:00 - 6:00 pm Networking Reception

6:00 - 6:45 pm Dinner

6:45 - 8:00 pm Panel Discussion



Allison Moore, PhD
Chief Technical Officer
Allogene Therapeutics



Robert Kiss, PhD
Vice President
Process/Analytical Development
Sutro Biopharma, Inc.



Kathy Yi
Chief Financial Officer
Sangamo Therapeutics

Program Manager: Feras Al-Zubaidy, Principal, Delta Project Management

Synopsis:

The ISPE Programs committee is developing an evening event to provide our Members with an overview of the latest developments and trends in the local biotech hub.

Allison Moore, PhD, CTO at Allogene Therapeutics, Robert Kiss, PhD, VP Process and Analytical Development at Sutro Biotherapeutics and Kathy Yi, Chief Financial Officer at Sangamo Therapeutics have kindly given up their time to spend with our community of Pharmaceutical Engineers to share their meaningful and personalized stories that speak to the state of the industry.

This event will explore ideas on why South San Francisco is such a hot market for latest trends in novel biotechnologies, what this means for emerging technologies and what effect the market and new emerging technologies will have for the young, modern Bay Area work force.



ISPE San Francisco/Bay Area Chapter's CEO Night **Tuesday, February 19, 2019**

About the Speakers

Allison Moore, PhD, Chief Technical Officer, Allogene Therapeutics

Dr. Moore is in charge of overseeing product sciences, supply chain, manufacturing, quality and technical operations. She has extensive experience in biomanufacturing and CMC product development, working in both Operations and Research and Development. She most recently served as Senior Vice President, Process Development at Amgen. Dr. Moore has previously held senior roles at Amgen in Operations Technology, Process and Product engineering, and Corporate Manufacturing. Prior to these positions, she was Vice President, Site Operations at Amgen's Fremont manufacturing facility. Before joining Amgen, Dr. Moore was a Director in Chemistry, Manufacturing and Controls, and Regulatory Affairs at Genentech.

Dr. Moore holds a PhD in Cell Biology from Manchester University, England, and a bachelor's in Pharmacology with Honors from Manchester University, England. She was a Postdoctoral Research Fellow at the Medical University of Lübeck, Germany, and at Genentech.

Robert Kiss, PhD, Vice President, Process and Analytical Development, Sutro Biopharma, Inc.

Dr. Robert Kiss has over 26 years of process development and manufacturing experience in the biotechnology industry. He came to Sutro after working at Genentech for nearly 24 years, where he most recently held the role of Distinguished Engineer and Senior Director of Late Stage Cell Culture process development. While at Genentech, he was directly involved in the development and initial licensure of the cell culture processes for Rituxan®, Herceptin®, Perjeta®, Tecentriq®, and Ocrevus™, the design and startup of the Vacaville manufacturing sites, and the transfer of multiple cell culture processes to Genentech/Roche and partner sites around the world.

He is globally-recognized for expertise in bioprocess scale-up, glycosylation of CHO-derived recombinant proteins, and virus barriers to protect mammalian cell culture processes. He received his chemical engineering degrees from UC Davis (BS) and the Massachusetts Institute of Technology (MS, PhD), is a Fellow in the American Institute of Medical and Biological Engineering, and is a licensed engineer in the state of California.

Kathy Yi, Senior Vice President and Chief Financial Officer, Sangamo Therapeutics

Kathy Yi has been with Sangamo for two years. She was formerly with Novartis Pharmaceuticals where she served as Head of Finance, Inhalation Technical Research & Development, responsible for the financial management of technical R&D organizations in California and Switzerland. Prior to joining Novartis, she was with Life Technologies Corp. from 2007 to 2014, during which time she held financial management positions of increasing seniority, including Finance Leader, Corporate FP&A. Prior to joining Life Technologies, Ms. Yi held various positions in finance at Intel Corp., from 2001 to 2007. She began her career as a Process/Project Engineer at Bechtel Corp., a leading global engineering, construction and project management company.

She received a BS degree in Chemical Engineering from the University of California at Berkeley and an MBA degree from Columbia Business School.



ISPE San Francisco/Bay Area Chapter's CEO Night **Tuesday, February 19, 2019**

About the Companies

Allogene Therapeutics

Allogene Therapeutics is a biotechnology company with a mission to catalyze the next revolution in cancer treatment through the development of allogeneic chimeric antigen receptor T-cell (CAR T) therapy directed at blood cancers and solid tumors. Founded and led by former Kite Pharma executives who bring unrivaled clinical development acumen in cell therapy, Allogene is well-positioned to further the potential of allogeneic cell therapy for patients.

Allogeneic CAR T therapies are engineered from cells of healthy donors and stored for “off-the-shelf” use in patients. This approach eliminates the need to create personalized therapy from a patient’s own cells, simplifies manufacturing, and reduces the time patients must wait for CAR T treatment. The Allogene portfolio includes 16 pre-clinical T cell therapy assets and UCART19, an allogeneic CAR T therapy currently in Phase 1 development for the treatment of acute lymphoblastic leukemia (ALL). Through its notable partnerships, Allogene leverages pioneering technology platforms, including TALEN® gene editing technology, to progress its portfolio of immunology therapies.

Sutro Biopharma, Inc.

Sutro's focus is aimed primarily on next generation cancer and autoimmune therapeutics — Antibody Conjugates, Bispecific Antibodies and Cytokine derivatives. Unconstrained by traditional methods of cell-based discovery, Sutro designs and develops targeted medicines by innovating outside the constraints of the cell. Their technology enables them to iteratively discover and test molecules in a rapid cycle of weeks rather than months, to rapidly identify the optimal molecule designed for safety and potency. Sutro's approach to discovery, without the cell, is also transcending the limitations of biologics manufacturing. Sutro has the world's only cGMP cell-free manufacturing facility located in San Carlos. This state-of-the-art facility confers an important competitive advantage as we head into human clinical trials in 2018. In addition to developing their own oncology pipeline, Sutro Biopharma is collaborating with select pharmaceutical and biotech companies to discover and develop novel, next generation therapeutics. As the pace of clinical development accelerates, Sutro and its partners are demonstrating a more efficient approach to killing tumors without harming healthy cells.

Sangamo Therapeutics

We are committed to translating ground-breaking science into genomic therapies that transform patients' lives. Accelerating toward the future of new genomic therapies – Since the first mapping of the human genome was completed 18 years ago, the progress of sequencing technology has accelerated exponentially. Every day we are learning more about the function and interplay of our genes, how they make us who we are, and how they contribute to human health and disease. The therapeutic potential of the genome is being unlocked.

Over that same time, Sangamo has forged the way toward the future of genomic therapies. Our scientists were the first to edit human cells and the first to conduct clinical trials with gene edited T cells. Recently, we initiated the first ever in vivo genome editing clinical trials. We have continued to perfect our zinc finger nuclease technology, which today sets the standards for genomic therapies along the three critical dimensions of specificity, precision, and efficiency.

Along the way, we have become experts across a range of genomic therapies, including genome editing, gene regulation, gene therapy and cell therapy. With this technological range and our development and manufacturing experience, Sangamo is uniquely prepared to deliver the new genomic therapies that will change the practice of medicine.



REGISTRATON FORM and INSTRUCTIONS CEO Night Tuesday, February 19, 2019

To Register and Receive an immediate receipt, use our on-line registration: <http://www.atdevents.net/register.php>
Name Badges will be given at the on-site registration desk.

ISPE California Chapter Members: If you are an ISPE Member in California, please do not set up a new account, as you should already be in our system. You will need your username (ISPE Member Number) and password to log on.

ISPE Members of Other Chapters: You will not be in our system unless you have previously set up an account. Please follow instructions for Non Members below. To update your account to a Member account, please forward your confirmation email from ISPE or your ISPE Membership information to Rob Fleming (rob.fleming@yahoo.com). We need your Chapter name, your ISPE Member number and expiration date. To retrieve this information, log onto the ISPE website. Click on "Account" on the top right side, then "My Account". Your Membership information (not including your chapter affiliation) is on the left side. Please take a screen shot or make a pdf of the page, then email it along with the name of your chapter to Rob Fleming to update your profile on the atdevents.net site.

Non Members: If you do not have an account on our system, you can set one up on the site using letters (not numbers) as your username.

FAX REGISTRATION: Fax your completed Registration Form with credit card payment to (949) 266-8461.

PAY BY CHECK: Register online to hold your spot. Make check payable to: ISPE San Francisco Chapter, 5319 University Dr., Suite 641, Irvine, CA 92612. Tel: 949-387-9046. Chapter Tax ID #68-0282494.

REGISTRATION HELP: If you need your username and/or password, help setting up your account or having problems with the online registration, please email Rob Fleming (rob.fleming@yahoo.com) for assistance.

Cancellations must be received in writing via fax or email to: ksyre@cox.net by February 11, 2019 for refund. After the cancellation date if you have reserved a space but do not attend, your payment MUST be remitted, however, if your alternate is a non-member, they will be required to pay the difference in fees. Name badges will be given at the event.

If paying by credit card, please check type of card:

_____ VISA _____ MASTERCARD _____ AMERICAN EXPRESS

Name on Card: _____

Card #: _____

Expiration Date: _____ Signature: _____

_____ \$95 ISPE Members _____ \$135 Non Members _____ \$40 Student or YP Members

NAME: _____

E-MAIL: _____

CELL: _____ TITLE: _____

COMPANY: _____

ADDRESS with MAIL CODE: _____

CITY, STATE, ZIP: _____

Getting There

AC Hotel San Francisco Airport/Oyster Point Waterfront

1333 Veterans Blvd., South San Francisco, CA 94080

Parking is complimentary

Arrive by car, BART, CalTrain, SamTrans or South San Francisco Bay Ferry. Click here for more information:

<http://covessf.com/main.cfm?sid=neighborhood&pid=transportation&img=transportation>

Driving Directions

From Emeryville:

Take 80 West, follow signs for San Francisco.
Take Bay Bridge to San Francisco (toll bridge).
Keep Left, follow signs for San Jose/US 101 S/Airport.
Merge onto 101 South.
Take Exit 425B for Oyster Point Blvd. E.
Continue onto Oyster Point Blvd.
Use the Left lane to turn Left onto Veterans Blvd.
The venue will be on the Left side.

From San Jose:

Take 101 North toward San Francisco.
Take Exit 425B for Oyster Point Blvd.
Use the middle lane to turn Left onto Dubuque Ave.
Use the 2nd from the right lane to turn Right onto Oyster Point Blvd.
Turn Left onto Veterans Blvd.
The venue will be on the Left side.

From Hayward/East Bay:

Take 92 West San Mateo Bridge (toll bridge).
Use the right 2 lanes to take exit 13B to merge onto 101 North toward San Francisco.
Take Exit 425B for Oyster Point Blvd.
Use the middle lane to turn Left onto Dubuque Ave.
Use the 2nd from the right lane to turn Right onto Oyster Point Blvd.
Turn Left onto Veterans Blvd.
The venue will be on the Left side.